<p>瑞穗證券分析師 Graig Suvannavejh 維持了對 EYPT 股票的看漲態度，並在 12 月 1 日給予買入評級。</p>
<h3>TipRanks 網絡星期一促銷</h3>
<ul>
<li>享受 TipRanks Premium 60% 的折扣，獲取數據支持的洞察和研究工具，讓您自信投資。</li>
<li>訂閲 TipRanks 的智能投資者精選，通過我們高表現的模型投資組合查看我們的數據 - 現在也享受 60% 的折扣。</li>
</ul>
<p>Graig Suvannavejh 的評級基於多種因素的綜合考慮，主要關注 EyePoint Pharmaceuticals 在競爭格局中的戰略定位。儘管競爭對手採取了加速審批策略，Suvannavejh 對 EyePoint 在臨牀試驗中的全面方法表示信心，特別是其產品 Duravyu。EyePoint 的第三階段試驗的全面性以及其之前第二階段數據的強勁表現為未來的成功奠定了堅實基礎。</p>
<p>此外，Suvannavejh 強調了競爭對手可能面臨的監管挑戰，這可能對 EyePoint 有利。競爭對手對有限數據的依賴可能無法滿足監管要求，從而可能延遲其市場進入。這種情況可能使 EyePoint 保持競爭優勢，並利用其對手面臨的任何挫折，從而鞏固其股票的買入評級。</p>
<p>Suvannavejh 覆蓋醫療保健領域，關注的股票包括 Terns Pharmaceuticals、EyePoint Pharmaceuticals 和 IDEAYA Biosciences。根據 TipRanks 的數據，Suvannavejh 推薦股票的平均回報率為 19.0%，成功率為 51.80%。</p>
<p>在 12 月 1 日發佈的另一份報告中，JonesTrading 也對該股票維持了買入評級，目標價為 43.00 美元。</p>

EYPT

<p>瑞穗證券分析師 Graig Suvannavejh 對 Eyepoint Pharmaceuticals 維持買入評級，理由是其戰略定位和競爭優勢。儘管競爭對手加快了審批策略，Eyepoint 的全面臨牀試驗和強勁的二期數據提供了堅實的基礎。競爭對手可能面臨的監管挑戰可能對 Eyepoint 有利。JonesTrading 也維持買入評級，目標價為 43.00 美元。Suvannavejh 在推薦股票上的平均回報率為 19.0%，成功率為 51.80%</p>

<p>Mizuho Securities analyst Graig Suvannavejh has maintained their bullish stance on EYPT stock, giving a Buy rating on December 1.</p>
<div class="lb-trans"><p>瑞穗證券分析師 Graig Suvannavejh 維持了對 EYPT 股票的看漲態度，並在 12 月 1 日給予買入評級。</p>
</div><h3>TipRanks Cyber Monday Sale</h3>
<div class="lb-trans"><h3>TipRanks 網絡星期一促銷</h3>
</div><ul>
<li>Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.</li>
<li>Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio -  now also 60% off</li>
</ul>
<div class="lb-trans"><ul>
<li>享受 TipRanks Premium 60% 的折扣，獲取數據支持的洞察和研究工具，讓您自信投資。</li>
<li>訂閲 TipRanks 的智能投資者精選，通過我們高表現的模型投資組合查看我們的數據 - 現在也享受 60% 的折扣。</li>
</ul>
</div><p>Graig Suvannavejh’s rating is based on a combination of factors, primarily focusing on the strategic positioning of EyePoint Pharmaceuticals in the competitive landscape. Despite a competitor’s accelerated approval strategy, Suvannavejh expresses confidence in EyePoint’s comprehensive approach to its clinical trials, particularly for its product Duravyu. The thoroughness of EyePoint’s Phase 3 trials and the strength of its previous Phase 2 data provide a solid foundation for future success.</p>
<div class="lb-trans"><p>Graig Suvannavejh 的評級基於多種因素的綜合考慮，主要關注 EyePoint Pharmaceuticals 在競爭格局中的戰略定位。儘管競爭對手採取了加速審批策略，Suvannavejh 對 EyePoint 在臨牀試驗中的全面方法表示信心，特別是其產品 Duravyu。EyePoint 的第三階段試驗的全面性以及其之前第二階段數據的強勁表現為未來的成功奠定了堅實基礎。</p>
</div><p>Furthermore, Suvannavejh highlights potential regulatory challenges faced by competitors, which could work in EyePoint’s favor. The reliance of competitors on limited data for approval may not meet regulatory requirements, potentially delaying their market entry. This scenario could allow EyePoint to maintain a competitive edge and capitalize on any setbacks faced by its rivals, reinforcing the Buy rating on its stock.</p>
<div class="lb-trans"><p>此外，Suvannavejh 強調了競爭對手可能面臨的監管挑戰，這可能對 EyePoint 有利。競爭對手對有限數據的依賴可能無法滿足監管要求，從而可能延遲其市場進入。這種情況可能使 EyePoint 保持競爭優勢，並利用其對手面臨的任何挫折，從而鞏固其股票的買入評級。</p>
</div><p>Suvannavejh covers the Healthcare sector, focusing on stocks such as Terns Pharmaceuticals, EyePoint Pharmaceuticals, and IDEAYA Biosciences. According to TipRanks, Suvannavejh has an average return of 19.0% and a 51.80% success rate on recommended stocks.</p>
<div class="lb-trans"><p>Suvannavejh 覆蓋醫療保健領域，關注的股票包括 Terns Pharmaceuticals、EyePoint Pharmaceuticals 和 IDEAYA Biosciences。根據 TipRanks 的數據，Suvannavejh 推薦股票的平均回報率為 19.0%，成功率為 51.80%。</p>
</div><p>In another report released on December 1, JonesTrading also maintained a Buy rating on the stock with a $43.00 price target.</p>
<div class="lb-trans"><p>在 12 月 1 日發佈的另一份報告中，JonesTrading 也對該股票維持了買入評級，目標價為 43.00 美元。</p>
</div>

Eyepoint Pharmaceuticals 的戰略定位和競爭優勢鞏固了其買入評級